A press release reports that Rexgenero has acquired all the key technology and program assets of aratinga.bio SAS Group. It adds that the acquisition, which follows the recent approval by the French Commercial Court, includes all patent applications and related intellectual property, the exclusive license agreement for polymeric nanoparticle technology and the bioproduction facilities [...]
Huw Jones Rexgenero has announced that Huw Jones has joined the company’s board as a non-executive director, and will chair the company’s remuneration committee. This follows the recent appointment of David Horn Solomon as chairman of Rexgenero’s Board. Huw is currently CEO of Chronos Therapeutics Limited (Chronos), a spin out from the [...]
Image credit: Rexgenero The first UK clinical trial site for the treatment of diabetic patients with chronic limb-threatening ischaemia using a novel patient-specific regenerative therapy has opened for patient recruitment at the University Hospital of Wales in Cardiff. The site will be evaluating REX-001 (Rexgenero) in two phase III trials codenamed the [...]